Tags

Type your tag names separated by a space and hit enter

[Results of short-term tuberculosis therapy with isoniazid, rifampicin and pyrazinamide].
Schweiz Med Wochenschr 1993; 123(25):1300-6SM

Abstract

Short-course chemotherapy of six-month duration with an initial combination of three drugs (isoniazid [H], rifampin [R] and pyrazinamide [Z]) is recommended as the treatment of choice in tuberculosis today. Use of fixed-combination tablet (Rifater) prevents prescription errors by physicians and selective intake by noncompliant patients. It should therefore assist in the prevention of emergence of drug resistance. In a controlled study at a chest hospital in Switzerland involving 261 patients with culture proven tuberculosis, the following two regimens were compared: 1) Six-month therapy (n = 128) with daily Rifater for two months, followed by H and R for four months. 2) Nine-month therapy (n = 133) with H and R daily for nine months, supplemented by ethambutol for the first two months. The two patient groups were comparable except for initial drug resistance (16% vs 8%, p < 0.05). Overall resistance to H was 10%. Five patients had initial resistance to two or more drugs. 227 patients were re-examined 1-8, and on average 4 years after therapy: four patients relapsed after 12, 20, 36 and 90 months. Two patients with initial drug resistance to H later developed resistance to R; both of these, as well as a third relapse patient, were cured with subsequent multi-drug therapy. Despite two and a half years of chemotherapy and repeated surgery, the fourth patient with initial resistance to H and R could not be cured. All relapse patients with initial drug resistance were randomized into the six-month therapy group.(

ABSTRACT

TRUNCATED AT 250 WORDS)

Authors+Show Affiliations

Zürcher Höhenklink Wald, Faltigberg-Wald.

Pub Type(s)

Case Reports
Clinical Trial
English Abstract
Journal Article
Randomized Controlled Trial

Language

ger

PubMed ID

8341998

Citation

Brändli, O, et al. "[Results of Short-term Tuberculosis Therapy With Isoniazid, Rifampicin and Pyrazinamide]." Schweizerische Medizinische Wochenschrift, vol. 123, no. 25, 1993, pp. 1300-6.
Brändli O, Dreher D, Morger D. [Results of short-term tuberculosis therapy with isoniazid, rifampicin and pyrazinamide]. Schweiz Med Wochenschr. 1993;123(25):1300-6.
Brändli, O., Dreher, D., & Morger, D. (1993). [Results of short-term tuberculosis therapy with isoniazid, rifampicin and pyrazinamide]. Schweizerische Medizinische Wochenschrift, 123(25), pp. 1300-6.
Brändli O, Dreher D, Morger D. [Results of Short-term Tuberculosis Therapy With Isoniazid, Rifampicin and Pyrazinamide]. Schweiz Med Wochenschr. 1993 Jun 26;123(25):1300-6. PubMed PMID: 8341998.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Results of short-term tuberculosis therapy with isoniazid, rifampicin and pyrazinamide]. AU - Brändli,O, AU - Dreher,D, AU - Morger,D, PY - 1993/6/26/pubmed PY - 1993/6/26/medline PY - 1993/6/26/entrez SP - 1300 EP - 6 JF - Schweizerische medizinische Wochenschrift JO - Schweiz Med Wochenschr VL - 123 IS - 25 N2 - Short-course chemotherapy of six-month duration with an initial combination of three drugs (isoniazid [H], rifampin [R] and pyrazinamide [Z]) is recommended as the treatment of choice in tuberculosis today. Use of fixed-combination tablet (Rifater) prevents prescription errors by physicians and selective intake by noncompliant patients. It should therefore assist in the prevention of emergence of drug resistance. In a controlled study at a chest hospital in Switzerland involving 261 patients with culture proven tuberculosis, the following two regimens were compared: 1) Six-month therapy (n = 128) with daily Rifater for two months, followed by H and R for four months. 2) Nine-month therapy (n = 133) with H and R daily for nine months, supplemented by ethambutol for the first two months. The two patient groups were comparable except for initial drug resistance (16% vs 8%, p < 0.05). Overall resistance to H was 10%. Five patients had initial resistance to two or more drugs. 227 patients were re-examined 1-8, and on average 4 years after therapy: four patients relapsed after 12, 20, 36 and 90 months. Two patients with initial drug resistance to H later developed resistance to R; both of these, as well as a third relapse patient, were cured with subsequent multi-drug therapy. Despite two and a half years of chemotherapy and repeated surgery, the fourth patient with initial resistance to H and R could not be cured. All relapse patients with initial drug resistance were randomized into the six-month therapy group.(ABSTRACT TRUNCATED AT 250 WORDS) SN - 0036-7672 UR - https://www.unboundmedicine.com/medline/citation/8341998/[Results_of_short_term_tuberculosis_therapy_with_isoniazid_rifampicin_and_pyrazinamide]_ L2 - http://www.diseaseinfosearch.org/result/7252 DB - PRIME DP - Unbound Medicine ER -